Request Demo
Last update 29 Aug 2026
Recombinant epidermal growth factor drop(Guilin Pavay Gene Pharmaceutical)
Last update 29 Aug 2026
Overview
Basic Info
Drug Type Growth factors |
Synonyms 易贝 |
Target |
Action modulators |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (12 Apr 2002), |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Recombinant epidermal growth factor drop(Guilin Pavay Gene Pharmaceutical)ITMCTR2024000386
Observation on the effect of Zhangyanming tablets combined with fluorometholone eye drops (0.02%) and human epidermal growth factor eye drops in the treatment of moderate and severe dry eye disease
CTR20130920
多中心、随机、双盲、阳性对照、剂量探索研究初步评价易贝治疗中度干眼伴浅层点状角膜病变的有效性及安全性
[Translation] A multicenter, randomized, double-blind, positive-controlled, dose-finding study to preliminarily evaluate the efficacy and safety of Yibei in the treatment of moderate dry eye with superficial punctate keratopathy
100 Clinical Results associated with Recombinant epidermal growth factor drop(Guilin Pavay Gene Pharmaceutical)
Login to view more data
100 Translational Medicine associated with Recombinant epidermal growth factor drop(Guilin Pavay Gene Pharmaceutical)
Login to view more data
100 Patents (Medical) associated with Recombinant epidermal growth factor drop(Guilin Pavay Gene Pharmaceutical)
Login to view more data
100 Deals associated with Recombinant epidermal growth factor drop(Guilin Pavay Gene Pharmaceutical)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Corneal Diseases | China | 12 Apr 2002 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Xerophthalmia | Phase 2 | China | 06 Nov 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free